Short-read Sequencing Market by Product (Consumables, Instruments, Software & Services), Technology (Semiconductor Sequencing, Sequencing Ligation, Sequencing Synthesis), End User, Application - Global Forecast 2025-2032
Description
The Short-read Sequencing Market was valued at USD 6.73 billion in 2024 and is projected to grow to USD 7.84 billion in 2025, with a CAGR of 16.43%, reaching USD 22.76 billion by 2032.
An authoritative overview of short-read sequencing dynamics emphasizing technological strengths, operational considerations, and the evolving ecosystem of instruments and informatics
Short-read sequencing remains a cornerstone technology for modern genomics workflows, providing rapid, high-throughput, and cost-efficient data generation that underpins discovery, clinical diagnostics, and translational research. Advances in instrument design, reagent chemistry, and computational pipelines have tightened turnaround times and improved data quality, enabling broader adoption across academic, clinical, and commercial settings. As a result, stakeholders across the life sciences value short-read platforms for established applications such as whole genome sequencing, targeted panels, and transcriptomic profiling, while also leveraging these platforms as complements to emerging long-read approaches.
In practice, the ecosystem around short-read sequencing extends far beyond instruments: consumables such as flow cells, reagents, and library preparation kits sustain recurring revenue streams and determine operational cost per sample, while software and bioinformatics services convert raw sequences into actionable insights. Moreover, differentiated offerings in benchtop versus high-throughput instruments influence how laboratories allocate capital and scale operations. Taken together, these dynamics create an environment where technical performance, total cost of ownership, and downstream analytics capabilities determine competitive positioning and adoption velocity.
Key technological and commercial inflection points redefining short-read sequencing adoption, integration, and clinical readiness across diverse laboratory settings
The short-read sequencing landscape is experiencing transformative shifts driven by technology refinement, clinical maturation, and strategic commercial realignment. Instrument vendors have intensified product development around throughput flexibility and operational simplicity, narrowing the gap between benchtop convenience and high-throughput capacity. At the same time, chemistry innovations have reduced error rates and improved read length consistency, strengthening the position of synthesis- and ligation-based approaches alongside semiconductor-driven platforms.
Concurrently, demand for integrated solutions is reshaping supplier strategies: laboratories increasingly prioritize bundled offerings that marry sequencers with validated reagents and certified bioinformatics pipelines to accelerate time-to-result and reduce integration risk. Clinical application growth-particularly in oncology and rare disease diagnostics-has compelled vendors to pursue regulatory clearances and co-development partnerships with healthcare providers. Finally, the proliferation of cloud-based data analysis and managed bioinformatics services is enabling institutions with limited in-house expertise to adopt complex genomic assays, thereby democratizing access and expanding the use-case footprint across research and clinical environments.
Assessment of how recent United States tariff adjustments through 2025 have altered procurement economics, supply chain resilience, and supplier manufacturing strategies in sequencing
The cumulative impact of recent United States tariff actions announced through 2025 has introduced new layers of complexity to procurement, supply chain planning, and pricing strategies for short-read sequencing stakeholders. Increased import duties on select laboratory equipment and consumables have elevated landed costs for instruments, flow cells, and reagents, prompting distributors and vendors to reassess pricing models and inventory strategies. In response, several suppliers have accelerated diversification of their manufacturing footprints to reduce exposure to tariff volatility, shifting select production lines to alternative regions or nearshoring critical components to maintain supply continuity and cost competitiveness.
In practical terms, end users experience a combination of higher direct costs and longer lead times for specialized components, which has driven tighter inventory management and a preference for suppliers offering predictable delivery and contractual price protections. Clinical laboratories and contract research providers have adapted by renegotiating service agreements to include fixed-price reagent subscriptions and by prioritizing platforms with robust local support networks. At the same time, some vendors have absorbed short-term tariff impact to preserve commercial momentum, while others have adjusted product mixes to emphasize higher-margin consumables and software services that are less exposed to import duties. Looking ahead, sustained tariff uncertainty will favor organizations that combine supply chain resilience, transparent pricing policies, and strategic partnerships to mitigate cost pressure and protect operational throughput.
Integrated segmentation insights linking product categories, technology platforms, end users, and application-specific workflows to reveal strategic commercial opportunities
A nuanced view of segmentation reveals distinct value pools and operational priorities across product, technology, end-user, and application categories. Based on Product, the ecosystem spans Consumables, Instruments, and Software & Services, with consumables such as flow cells and reagents and library prep kits driving recurring spend and determining per-sample economics; instruments split between benchtop sequencers and high-throughput sequencers influence capital allocation and workflow scalability; and Software & Services, encompassing bioinformatics services and data analysis software, enable downstream interpretation and regulatory compliance. Based on Technology, the landscape includes semiconductor sequencing, sequencing ligation, and sequencing synthesis, where semiconductor approaches such as Ion Proton and Ion Torrent PGM have historically offered unique trade-offs in speed and cost-per-run while synthesis and ligation chemistries compete on accuracy and read-length characteristics. Based on End User, adoption patterns vary across academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharma and biotech companies, each segment driven by differing throughput needs, regulatory pressures, and budget cycles. Based on Application, core uses include epigenomics, genomics, metagenomics, and transcriptomics; within epigenomics, focus areas such as chromatin accessibility analysis and DNA methylation analysis serve specific research and clinical workflows, while genomics applications like resequencing, targeted sequencing, and whole genome sequencing address discovery and diagnostic objectives.
These segmentation lenses intersect to create targeted opportunities: for example, clinical diagnostic labs prioritize validated consumable bundles paired with certified data analysis software, whereas academic centers emphasize flexible benchtop instruments and open-source pipelines to support exploratory applications across transcriptomics and metagenomics. Industry participants that map product and technology choices to end-user workflows and application demands will be better positioned to design differentiated commercial models and support frameworks that align with customer procurement cycles and regulatory considerations.
Comparative regional analysis outlining how geographic differences in research capacity, clinical adoption, and industrial policy shape sequencing supply and demand dynamics
Regional dynamics continue to shape adoption trajectories and supplier strategies as different geographies balance research intensity, clinical demand, and industrial policy. In the Americas, strong academic ecosystems, centralized sequencing hubs, and an expanding clinical genomics market have driven demand for both benchtop flexibility and high-throughput capacity, while policy and reimbursement nuances influence how quickly genomic assays move into routine care. In Europe, Middle East & Africa, adoption is heterogeneous: leading research centers and national genomics initiatives in Western Europe coexist with emerging capacities in other markets, with regulatory harmonization and cross-border collaborations influencing procurement and data governance. In Asia-Pacific, rapid investment in biopharmaceutical development, large-scale population genomics initiatives, and growing local manufacturing capabilities have accelerated uptake of diverse sequencing platforms and consumables.
These regional factors affect vendor go-to-market approaches, including the degree of localization required for service support, the need for regulatory dossiers tailored to specific jurisdictions, and the importance of strategic distribution partnerships. Suppliers that customize product offerings and commercial terms to align with regional reimbursement frameworks, laboratory accreditation requirements, and data sovereignty expectations are more likely to achieve sustainable adoption and long-term partnerships with regional stakeholders.
How top industry players are aligning product innovation, integrated informatics, and flexible commercial models to deepen customer relationships and secure recurring revenue
Leading companies in the short-read sequencing ecosystem are pursuing a mix of product innovation, strategic partnerships, and commercial model evolution to capture value across instruments, consumables, and informatics. Vendors are investing in platform modularity to serve both low-throughput clinical labs and high-throughput research centers, while product roadmaps prioritize reduced hands-on time, automated library preparation, and improved chemistry stability to lower operational friction. Simultaneously, companies are strengthening software and services capabilities through acquisitions or in-house development of bioinformatics suites and managed analysis services, recognizing that data interpretation and regulatory-ready pipelines are increasingly the differentiators in competitive tenders.
Commercially, firms are experimenting with subscription models, reagent-as-a-service contracts, and outcome-based pricing to lock in recurring revenue and align incentives with customers. Partnerships between instrument providers, reagent manufacturers, and cloud analytics companies are becoming more commonplace to deliver end-to-end validated workflows. Moreover, several firms are expanding manufacturing capacity and strategic distribution to mitigate supply chain risk and tariff exposure. The strategic imperative is clear: firms that marry platform performance with robust downstream analytics, dependable service networks, and flexible commercial propositions will secure deeper, longer-term relationships with institutional customers and clinical laboratories.
A pragmatic playbook for industry leaders to strengthen supply chains, commercial models, and integrated workflow offerings to accelerate adoption and resilience
Industry leaders should prioritize a pragmatic set of actions to navigate current headwinds while accelerating growth opportunities. First, diversify manufacturing and supplier relationships to reduce exposure to tariff fluctuations and single-source bottlenecks, and consider nearshoring critical reagent production to stabilize lead times. Second, invest in validated, turnkey workflows that bundle sequencers with certified consumables and regulatory-ready bioinformatics to reduce customer integration costs and shorten sales cycles. Third, expand service offerings through managed analytics and training programs that enable adoption in resource-constrained clinical and research settings, thereby creating sticky revenue streams beyond initial instrument sales.
In addition, companies should refine commercial models to include subscription and reagent-consumption agreements that align vendor incentives with customer throughput and clinical outcomes. Strengthen regional go-to-market strategies by tailoring regulatory support and service footprints to local accreditation and data governance requirements. Finally, prioritize strategic partnerships and selective acquisitions to build capabilities in cloud-enabled analysis, AI-driven variant interpretation, and specialized library preparation chemistries that target high-value clinical applications. These steps will help organizations mitigate near-term supply and pricing pressures while building differentiated offerings that capture long-term demand across research and clinical segments.
A transparent research methodology blending primary expert interviews, rigorous literature synthesis, and triangulation to validate conclusions and recommendations
The research underpinning this report combined structured primary engagement with domain experts and stakeholders, systematic review of contemporary scientific literature, and triangulation against publicly available regulatory filings and vendor technical documentation. Primary inputs included interviews with laboratory directors, procurement leads, clinical validation specialists, and senior product managers representing academic, clinical, and commercial end users. These discussions focused on procurement drivers, operational constraints, and adoption criteria for instruments, consumables, and informatics solutions.
Secondary research involved synthesis of peer-reviewed studies, standards and guidelines from regulatory authorities, white papers describing sequencing chemistries and instrument performance, and company disclosures that clarify product roadmaps and commercial strategies. Data integrity was reinforced through cross-validation between primary insights and secondary evidence, and methodological transparency was maintained by documenting assumptions, inclusion criteria for technologies and applications, and the segmentation framework. Finally, findings were reviewed by an external expert panel to stress-test interpretations and ensure the report’s recommendations are actionable and relevant across diverse operational contexts.
A concise synthesis of the strategic implications for suppliers and end users highlighting resilience, integration, and application-driven differentiation
In conclusion, short-read sequencing continues to offer compelling value across discovery, translational research, and clinical diagnostics by delivering reliable, high-throughput data at operationally attractive throughput and cost profiles. The ecosystem is maturing: consumables and informatics are now as strategically important as instrument performance in defining customer value, while tariff dynamics and regional policy variations are reshaping supply chain and commercial strategies. Consequently, organizations that adopt integrated, customer-centric approaches-bundling validated reagents, streamlined workflows, and robust analytics-will unlock faster adoption and deeper commercial relationships.
Moving forward, resilience will be as crucial as innovation. Firms that proactively diversify manufacturing, refine flexible pricing and service models, and invest in regulatory readiness and local support will be best positioned to capture demand across academic, clinical, and commercial segments. The interplay among product segmentation, technology choices, end-user requirements, and application-specific needs will continue to define competitive advantage, placing a premium on partners that can translate technical excellence into dependable, actionable solutions for laboratories and healthcare providers.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative overview of short-read sequencing dynamics emphasizing technological strengths, operational considerations, and the evolving ecosystem of instruments and informatics
Short-read sequencing remains a cornerstone technology for modern genomics workflows, providing rapid, high-throughput, and cost-efficient data generation that underpins discovery, clinical diagnostics, and translational research. Advances in instrument design, reagent chemistry, and computational pipelines have tightened turnaround times and improved data quality, enabling broader adoption across academic, clinical, and commercial settings. As a result, stakeholders across the life sciences value short-read platforms for established applications such as whole genome sequencing, targeted panels, and transcriptomic profiling, while also leveraging these platforms as complements to emerging long-read approaches.
In practice, the ecosystem around short-read sequencing extends far beyond instruments: consumables such as flow cells, reagents, and library preparation kits sustain recurring revenue streams and determine operational cost per sample, while software and bioinformatics services convert raw sequences into actionable insights. Moreover, differentiated offerings in benchtop versus high-throughput instruments influence how laboratories allocate capital and scale operations. Taken together, these dynamics create an environment where technical performance, total cost of ownership, and downstream analytics capabilities determine competitive positioning and adoption velocity.
Key technological and commercial inflection points redefining short-read sequencing adoption, integration, and clinical readiness across diverse laboratory settings
The short-read sequencing landscape is experiencing transformative shifts driven by technology refinement, clinical maturation, and strategic commercial realignment. Instrument vendors have intensified product development around throughput flexibility and operational simplicity, narrowing the gap between benchtop convenience and high-throughput capacity. At the same time, chemistry innovations have reduced error rates and improved read length consistency, strengthening the position of synthesis- and ligation-based approaches alongside semiconductor-driven platforms.
Concurrently, demand for integrated solutions is reshaping supplier strategies: laboratories increasingly prioritize bundled offerings that marry sequencers with validated reagents and certified bioinformatics pipelines to accelerate time-to-result and reduce integration risk. Clinical application growth-particularly in oncology and rare disease diagnostics-has compelled vendors to pursue regulatory clearances and co-development partnerships with healthcare providers. Finally, the proliferation of cloud-based data analysis and managed bioinformatics services is enabling institutions with limited in-house expertise to adopt complex genomic assays, thereby democratizing access and expanding the use-case footprint across research and clinical environments.
Assessment of how recent United States tariff adjustments through 2025 have altered procurement economics, supply chain resilience, and supplier manufacturing strategies in sequencing
The cumulative impact of recent United States tariff actions announced through 2025 has introduced new layers of complexity to procurement, supply chain planning, and pricing strategies for short-read sequencing stakeholders. Increased import duties on select laboratory equipment and consumables have elevated landed costs for instruments, flow cells, and reagents, prompting distributors and vendors to reassess pricing models and inventory strategies. In response, several suppliers have accelerated diversification of their manufacturing footprints to reduce exposure to tariff volatility, shifting select production lines to alternative regions or nearshoring critical components to maintain supply continuity and cost competitiveness.
In practical terms, end users experience a combination of higher direct costs and longer lead times for specialized components, which has driven tighter inventory management and a preference for suppliers offering predictable delivery and contractual price protections. Clinical laboratories and contract research providers have adapted by renegotiating service agreements to include fixed-price reagent subscriptions and by prioritizing platforms with robust local support networks. At the same time, some vendors have absorbed short-term tariff impact to preserve commercial momentum, while others have adjusted product mixes to emphasize higher-margin consumables and software services that are less exposed to import duties. Looking ahead, sustained tariff uncertainty will favor organizations that combine supply chain resilience, transparent pricing policies, and strategic partnerships to mitigate cost pressure and protect operational throughput.
Integrated segmentation insights linking product categories, technology platforms, end users, and application-specific workflows to reveal strategic commercial opportunities
A nuanced view of segmentation reveals distinct value pools and operational priorities across product, technology, end-user, and application categories. Based on Product, the ecosystem spans Consumables, Instruments, and Software & Services, with consumables such as flow cells and reagents and library prep kits driving recurring spend and determining per-sample economics; instruments split between benchtop sequencers and high-throughput sequencers influence capital allocation and workflow scalability; and Software & Services, encompassing bioinformatics services and data analysis software, enable downstream interpretation and regulatory compliance. Based on Technology, the landscape includes semiconductor sequencing, sequencing ligation, and sequencing synthesis, where semiconductor approaches such as Ion Proton and Ion Torrent PGM have historically offered unique trade-offs in speed and cost-per-run while synthesis and ligation chemistries compete on accuracy and read-length characteristics. Based on End User, adoption patterns vary across academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharma and biotech companies, each segment driven by differing throughput needs, regulatory pressures, and budget cycles. Based on Application, core uses include epigenomics, genomics, metagenomics, and transcriptomics; within epigenomics, focus areas such as chromatin accessibility analysis and DNA methylation analysis serve specific research and clinical workflows, while genomics applications like resequencing, targeted sequencing, and whole genome sequencing address discovery and diagnostic objectives.
These segmentation lenses intersect to create targeted opportunities: for example, clinical diagnostic labs prioritize validated consumable bundles paired with certified data analysis software, whereas academic centers emphasize flexible benchtop instruments and open-source pipelines to support exploratory applications across transcriptomics and metagenomics. Industry participants that map product and technology choices to end-user workflows and application demands will be better positioned to design differentiated commercial models and support frameworks that align with customer procurement cycles and regulatory considerations.
Comparative regional analysis outlining how geographic differences in research capacity, clinical adoption, and industrial policy shape sequencing supply and demand dynamics
Regional dynamics continue to shape adoption trajectories and supplier strategies as different geographies balance research intensity, clinical demand, and industrial policy. In the Americas, strong academic ecosystems, centralized sequencing hubs, and an expanding clinical genomics market have driven demand for both benchtop flexibility and high-throughput capacity, while policy and reimbursement nuances influence how quickly genomic assays move into routine care. In Europe, Middle East & Africa, adoption is heterogeneous: leading research centers and national genomics initiatives in Western Europe coexist with emerging capacities in other markets, with regulatory harmonization and cross-border collaborations influencing procurement and data governance. In Asia-Pacific, rapid investment in biopharmaceutical development, large-scale population genomics initiatives, and growing local manufacturing capabilities have accelerated uptake of diverse sequencing platforms and consumables.
These regional factors affect vendor go-to-market approaches, including the degree of localization required for service support, the need for regulatory dossiers tailored to specific jurisdictions, and the importance of strategic distribution partnerships. Suppliers that customize product offerings and commercial terms to align with regional reimbursement frameworks, laboratory accreditation requirements, and data sovereignty expectations are more likely to achieve sustainable adoption and long-term partnerships with regional stakeholders.
How top industry players are aligning product innovation, integrated informatics, and flexible commercial models to deepen customer relationships and secure recurring revenue
Leading companies in the short-read sequencing ecosystem are pursuing a mix of product innovation, strategic partnerships, and commercial model evolution to capture value across instruments, consumables, and informatics. Vendors are investing in platform modularity to serve both low-throughput clinical labs and high-throughput research centers, while product roadmaps prioritize reduced hands-on time, automated library preparation, and improved chemistry stability to lower operational friction. Simultaneously, companies are strengthening software and services capabilities through acquisitions or in-house development of bioinformatics suites and managed analysis services, recognizing that data interpretation and regulatory-ready pipelines are increasingly the differentiators in competitive tenders.
Commercially, firms are experimenting with subscription models, reagent-as-a-service contracts, and outcome-based pricing to lock in recurring revenue and align incentives with customers. Partnerships between instrument providers, reagent manufacturers, and cloud analytics companies are becoming more commonplace to deliver end-to-end validated workflows. Moreover, several firms are expanding manufacturing capacity and strategic distribution to mitigate supply chain risk and tariff exposure. The strategic imperative is clear: firms that marry platform performance with robust downstream analytics, dependable service networks, and flexible commercial propositions will secure deeper, longer-term relationships with institutional customers and clinical laboratories.
A pragmatic playbook for industry leaders to strengthen supply chains, commercial models, and integrated workflow offerings to accelerate adoption and resilience
Industry leaders should prioritize a pragmatic set of actions to navigate current headwinds while accelerating growth opportunities. First, diversify manufacturing and supplier relationships to reduce exposure to tariff fluctuations and single-source bottlenecks, and consider nearshoring critical reagent production to stabilize lead times. Second, invest in validated, turnkey workflows that bundle sequencers with certified consumables and regulatory-ready bioinformatics to reduce customer integration costs and shorten sales cycles. Third, expand service offerings through managed analytics and training programs that enable adoption in resource-constrained clinical and research settings, thereby creating sticky revenue streams beyond initial instrument sales.
In addition, companies should refine commercial models to include subscription and reagent-consumption agreements that align vendor incentives with customer throughput and clinical outcomes. Strengthen regional go-to-market strategies by tailoring regulatory support and service footprints to local accreditation and data governance requirements. Finally, prioritize strategic partnerships and selective acquisitions to build capabilities in cloud-enabled analysis, AI-driven variant interpretation, and specialized library preparation chemistries that target high-value clinical applications. These steps will help organizations mitigate near-term supply and pricing pressures while building differentiated offerings that capture long-term demand across research and clinical segments.
A transparent research methodology blending primary expert interviews, rigorous literature synthesis, and triangulation to validate conclusions and recommendations
The research underpinning this report combined structured primary engagement with domain experts and stakeholders, systematic review of contemporary scientific literature, and triangulation against publicly available regulatory filings and vendor technical documentation. Primary inputs included interviews with laboratory directors, procurement leads, clinical validation specialists, and senior product managers representing academic, clinical, and commercial end users. These discussions focused on procurement drivers, operational constraints, and adoption criteria for instruments, consumables, and informatics solutions.
Secondary research involved synthesis of peer-reviewed studies, standards and guidelines from regulatory authorities, white papers describing sequencing chemistries and instrument performance, and company disclosures that clarify product roadmaps and commercial strategies. Data integrity was reinforced through cross-validation between primary insights and secondary evidence, and methodological transparency was maintained by documenting assumptions, inclusion criteria for technologies and applications, and the segmentation framework. Finally, findings were reviewed by an external expert panel to stress-test interpretations and ensure the report’s recommendations are actionable and relevant across diverse operational contexts.
A concise synthesis of the strategic implications for suppliers and end users highlighting resilience, integration, and application-driven differentiation
In conclusion, short-read sequencing continues to offer compelling value across discovery, translational research, and clinical diagnostics by delivering reliable, high-throughput data at operationally attractive throughput and cost profiles. The ecosystem is maturing: consumables and informatics are now as strategically important as instrument performance in defining customer value, while tariff dynamics and regional policy variations are reshaping supply chain and commercial strategies. Consequently, organizations that adopt integrated, customer-centric approaches-bundling validated reagents, streamlined workflows, and robust analytics-will unlock faster adoption and deeper commercial relationships.
Moving forward, resilience will be as crucial as innovation. Firms that proactively diversify manufacturing, refine flexible pricing and service models, and invest in regulatory readiness and local support will be best positioned to capture demand across academic, clinical, and commercial segments. The interplay among product segmentation, technology choices, end-user requirements, and application-specific needs will continue to define competitive advantage, placing a premium on partners that can translate technical excellence into dependable, actionable solutions for laboratories and healthcare providers.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI-driven variant calling algorithms to improve short-read sequencing accuracy and throughput
- 5.2. Rising adoption of automation and robotics in sample preparation workflows for high-throughput short-read sequencing
- 5.3. Expansion of portable benchtop sequencers enabling point-of-care genetic testing in clinical microbiology labs
- 5.4. Development of novel library preparation kits for ultra-low input and degraded DNA samples in forensic genomics
- 5.5. Increased use of multiplexed target enrichment panels for comprehensive cancer mutation profiling at lower costs
- 5.6. Collaboration between sequencing providers and cloud computing platforms for real-time data analysis scalability
- 5.7. Regulatory focus on standardization of sequencing quality metrics to facilitate clinical adoption of short-read platforms
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Short-read Sequencing Market, by Product
- 8.1. Consumables
- 8.1.1. Flow Cells & Reagents
- 8.1.2. Library Prep Kits
- 8.2. Instruments
- 8.2.1. Benchtop Sequencers
- 8.2.2. High-Throughput Sequencers
- 8.3. Software & Services
- 8.3.1. Bioinformatics Services
- 8.3.2. Data Analysis Software
- 9. Short-read Sequencing Market, by Technology
- 9.1. Semiconductor Sequencing
- 9.1.1. Ion Proton
- 9.1.2. Ion Torrent PGM
- 9.2. Sequencing Ligation
- 9.3. Sequencing Synthesis
- 10. Short-read Sequencing Market, by End User
- 10.1. Academic & Research Institutes
- 10.2. Contract Research Organizations
- 10.3. Hospitals & Diagnostic Labs
- 10.4. Pharma & Biotech Companies
- 11. Short-read Sequencing Market, by Application
- 11.1. Epigenomics
- 11.1.1. Chromatin Accessibility Analysis
- 11.1.2. DNA Methylation Analysis
- 11.2. Genomics
- 11.2.1. Resequencing
- 11.2.2. Targeted Sequencing
- 11.2.3. Whole Genome Sequencing
- 11.3. Metagenomics
- 11.4. Transcriptomics
- 12. Short-read Sequencing Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Short-read Sequencing Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Short-read Sequencing Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Illumina, Inc.
- 15.3.2. Thermo Fisher Scientific Inc.
- 15.3.3. F. Hoffmann-La Roche Ltd
- 15.3.4. BGI Genomics Co., Ltd.
- 15.3.5. Pacific Biosciences of California, Inc.
- 15.3.6. Qiagen N.V.
- 15.3.7. Agilent Technologies, Inc.
- 15.3.8. Oxford Nanopore Technologies plc
- 15.3.9. PerkinElmer, Inc.
- 15.3.10. Danaher Corporation
- 15.3.11. Bio-Rad Laboratories, Inc.
- 15.3.12. GE HealthCare Technologies Inc.
- 15.3.13. Hamilton Company
- 15.3.14. Eppendorf SE
- 15.3.15. Takara Bio Inc.
- 15.3.16. Macrogen, Inc.
- 15.3.17. Eurofins Scientific SE
- 15.3.18. Genewiz, Inc.
- 15.3.19. Psomagen, Inc.
- 15.3.20. Novogene Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
